Sign Up for a Free Account
  • Updated 07.08.2020
  • Released 07.06.1999
  • Expires For CME 07.08.2023



Historical note and terminology

Methylphenidate was approved by the United States Food and Drug Administration in 1956. It is the most widely used psychostimulant for attention deficit hyperactivity disorder and accounts for 69% of the market for these drugs.

In 2000, the Food and Drug Administration approved an extended release preparation of methylphenidate hydrochloride for once daily dosing. A refined formulation of methylphenidate, dexmethylphenidate hydrochloride, is available. Some controversy has been generated, mostly by public groups, expressing concern at the excessive use of psychostimulants in attention deficit hyperactivity disorders and even raising the possibility of overdiagnosis of this disorder. No scientific evidence has emerged to support this concern.

Start a MedLink Neurology trial
to unlock 3 free articles.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660